1.Effectiveness of postoperative adjuvant treatment between radiation alone and chemotherapy plus radiation in locally advanced breast cancer.
Kyung Ran PARK ; John Kyu LOH JUHN ; Chang Ok SUH ; Gwi Eon KIM ; Eun Hee KOH ; Byung Soo KIM ; Kyung Sik LEE
Journal of the Korean Cancer Association 1991;23(1):107-119
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
2.The effect of inductive chemotherapy with FAC regimen on breast cancer.
Journal of the Korean Cancer Association 1991;23(4):783-789
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
3.Chemotherapy of breast cancer.
Korean Journal of Medicine 2000;58(5):497-509
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
4.Quadrantectomy and axillary node dissection in breast cancer after preoperative inductive chemotherapy.
Journal of the Korean Cancer Association 1992;24(6):840-847
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
5.Systemic adjuvant therapy in breast cancer.
Jin Hee AHN ; Sung Bae KIM ; Woo Kun KIM
Korean Journal of Medicine 2005;69(3):243-254
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy
;
Neoadjuvant Therapy
6.The effect of adjuvant CMF(cyclophosphamide, methotrexate, 5-FU) chemotherapy of breast cancer.
Joon PARK ; Jung Han YOON ; Young Jong JEGAL
Journal of the Korean Cancer Association 1993;25(6):928-934
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
;
Methotrexate*
7.Mono- and Combination Chemotherapy for Metastatic Breast Cancer: An Increamental Step Forward.
Journal of Korean Breast Cancer Society 2003;6(3):137-140
No abstract available.
Breast Neoplasms*
;
Breast*
;
Drug Therapy, Combination*
8.Clinical and pathologic tumor response following response-guided neoadjuvant chemotherapy for locally-advanced breast cancer in a Tertiary Hospital Breast Center in the Philippines
Shiela S. Macalindong ; Ralph Lazarus R. Rapacon
Philippine Journal of Surgical Specialties 2024;79(1):42-53
Rationale/Objective:
Neoadjuvant chemotherapy (NAC) is
recommended for locally-advanced breast cancer (LABC) to improve
resectability and provide in-vivo tumor response assessment. This
study aimed to describe the clinical and pathologic tumor response
of LABC patients after response-guided NAC.
Methods:
This is a retrospective cohort analysis of 128 LABC patients
who underwent NAC using sequential doxorubicin/cyclophosphamide
(AC) – docetaxel (T) regimen at the Philippine General Hospital
Breast Care Center. Clinical and pathologic response rates were
analyzed according to clinicopathologic variables including tumor
intrinsic subtype.
Results:
Objective clinical response (complete and partial) was
observed in 88% (111/128) of patients with 11% (14/128) achieving
pathologic complete response (pCR). The hormone receptor-negative/
Her2-enriched (HR-/Her2+) subtype had the highest pCR rate (23.5%)
followed by triple negative subtype (HR-/Her2-) at 19%. The hormone
receptor-positive/Her2-positive (HR+/Her2+) subtype had the lowest
pCR (4.7%). Two patients with initial poor response to AC but had
good response upon shifting to T achieved pCR. Twelve patients
(9.4%) had poor response to AC and T chemotherapy. Patients who
were pre-menopausal (p=0.04), had ductal histology (p=0.03), with
a HR-/Her2- (p=0.002) or HR+/Her2+ subtype (p=0.03) had good
response to AC. Intrinsic subtype was not significantly associated
with treatment response in those who received docetaxel. There was
strong association between the pathologic and clinical responses
(Spearman’s Rho score 0.69, p-value <0.0001).
Conclusion
Clinical and pathologic response to NAC was highly
dependent on tumor subtype. Clinical response was predictive of
pathologic response. Response-guided NAC allowed direct and early
evaluation of tumor treatment response that allowed for treatment
modifications.
Breast Neoplasms
;
Neoadjuvant Therapy
;
Drug Therapy
9.The Reliability of Histoculture Drug Response Assay (HDRA) in Chemosensitivity Tests for Breast Cancer.
Hee Joon KANG ; Chang Dae KO ; Ho Sung YOON ; Moon Bo KIM ; Sei Hyun AHN
Cancer Research and Treatment 2001;33(5):392-397
PURPOSE: Cancers are highly individual in their response to chemotherapy, however attempts to predict tumor response to drugs using in vitro cell culture have largely failed. A new technology, the histoculture drug response assay (HDRA), appears to have solved many previous problems. The purpose of this study is to evaluate the reliability of HDRA in a chemosensitivity test for breast cancer. MATERIALS AND METHODS: Tumor specimens from breast cancer patients were evaluated by HDRA using different chemotherapeutic agents. Each specimen was tested using a blind method in order to determine the reproducibility of HDRA results for the same tissue and with a triplicated assay in order to determine reproducibility by different examiners. The evaluative power of this assay and the chemosensitivity of drugs for each specimen was determined. RESULTS: Specimens of 92.9% (65/70) were successfully cultured and evaluated for chemosensitivity. The reproducibility of HDRA for the same tissue was 75% (100% agreement) and 100% (over 70% agreement), respectively. And the reproducibility by different examiners was 78.9% (100% agreement) and 94.7% (over 70% agreement), respectively. Each specimen demonstrated a response to at least one agent. CONCLUSION: The evaluative power and reproducibility of HDRA were high, therefore it might serve as a reliable clinical method for chemosensitivity testing. However, there is a need for clinical trial in which patients are initially randomized for treatment either by HDRA direction or by clinician's choice.
Breast Neoplasms*
;
Breast*
;
Cell Culture Techniques
;
Drug Therapy
;
Humans
10.RECIST Criteria for Tumor Response in the Patients with Breast Cancer Who Had Neoadjuvant Chemotherapy.
Jae Cheong LEE ; Ja Seong BAE ; Mi Ra KIM ; Woo Chan PARK ; Byong Ju SONG ; Jeong Soo KIM ; Sang Seol JUNG
Journal of the Korean Surgical Society 2007;72(2):89-93
PURPOSE: This study compared the response evaluation using the WHO (World Health Organization) criteria for patients with breast cancer with that of the RECIST (Response Evaluation Criteria In Solid Tumor) criteria in order to determine the significance of the RECIST criteria in breast cancer. METHODS: Between 2001 and 2005, 42 patients with measurable lesions radiologically receiving neoadjuvant chemotherapy for a breast carcinoma were enrolled in this study. The results were compared using a kappa test as a concordance measure between the two response criteria. RESULTS: With the WHO criteria, the overall response and progression rate were 35.7% (CR 0, PR 15) and 16.6% (PD 7) respectively. On the other hand, the overall response and progression rate using the RECIST criteria were 38.0% (CR 0, PR 16) and 7% (PD 3) respectively. The kappa value as a concordance measure between two response criteria was 0.718. CONCLUSION: The RECIST criteria are comparable to the WHO criteria in evaluating the response of breast cancer patients who have undergone neoadjuvant chemotherapy. A comparison of these results with other studies of more common tumor types supports the implementation of RECIST as the standard criteria for evaluating the treatment response but also for monitoring progression.
Breast Neoplasms*
;
Breast*
;
Drug Therapy*
;
Hand
;
Humans
;
World Health Organization